Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312183 | 0.90 | PDE4B (0.59) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL13865612 | 0.89 | PDE4B (0.63) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL13870220 | 0.89 | PDE4B (0.58) | PDE4BPDE3BPDE7APDE3A | |
| Hydrochloric Acid SCHEMBL2773651 | 0.89 | PDE4B (0.62) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL221173 | 0.88 | PDE4B (0.61) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL2775159 | 0.88 | PDE4B (0.55) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL13870254 | 0.87 | PDE4B (0.54) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL2773212 | 0.86 | PDE4B (0.54) | PDE4BPDE3BPDE7APDE3A | |
| SCHEMBL222815 | 0.85 | PDE4B (0.72) | PDE4B | |
| SCHEMBL2774528 | 0.82 | PDE4B (0.76) | PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581532-B1 | PYRAZOLO¬3,4-B PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| WO-2004056823-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252790-A1 | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885PDE3B 3/4885PDE7A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.